Mauro Ferrari
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Mauro Ferrari has a total of 127 co-authors. Here are the top co-authors by number of shared publications:
- Haifa Shen
Department of Nanomedicine, The Methodist Hospital Research Institute, Houston, Texas 77030, USA
8 shared publications Xuewu Liu
Department of Nanomedicine, The Methodist Hospital Research Institute, 6670 Bertner Avenue, Houston, Texas 77030, USA
7 shared publicationsHaifa Shen
Department of Nanomedicine, Houston Methodist Research Institute, Houston, TX 77030, USA; Department of Cell and Developmental Biology, Weill Cornell Medical College, New York, NY 10065, USA
6 shared publications- Joy Wolfram
School of Chemical Engineering The University of Queensland Brisbane Queensland Australia
5 shared publications - Biana Godin
Center for BioNanoengineering, Houston Methodist Hospital, Houston, USA
4 shared publications Elvin Blanco
Department of Nanomedicine, The Houston Methodist Research Institute, Houston, Texas, USA
4 shared publications
Latest Publications
- Open Access
- 1 August 2016
- Published by Wolters Kluwer Health in Transplantation
- Vol. 100 (8) , 1629-1638
The Emerging Role of Nanotechnology in Cell and Organ Transplantation
Transplantation is often the only choice many patients have when suffering from end-stage organ failure. Although the quality of life improves after transplantation, challenges, such as organ shortages, necessary immunosuppression with associated complications, and chronic graft rejection, limit its wide clinical application. Nanotechnology has emerged in the past 2 decades as a field with the potential to satisfy clinical needs in the area of targeted and sustained drug delivery, noninvasive imaging, and tissue engineering. In this article, we provide an overview of popular nanotechnologies and a summary of the current and potential uses of nanotechnology in cell and organ transplantation.
- 1 August 2016
- Published by Wolters Kluwer Health in Transplantation
- Vol. 100 (8) , 1629-1638
Open AccessThe Emerging Role of Nanotechnology in Cell and Organ Transplantation
Transplantation is often the only choice many patients have when suffering from end-stage organ failure. Although the quality of life improves after transplantation, challenges, such as organ shortages, necessary immunosuppression with associated complications, and chronic graft rejection, limit its wide clinical application. Nanotechnology has emerged in the past 2 decades as a field with the potential to satisfy clinical needs in the area of targeted and sustained drug delivery, noninvasive imaging, and tissue engineering. In this article, we provide an overview of popular nanotechnologies and a summary of the current and potential uses of nanotechnology in cell and organ transplantation.
- Open Access
- 1 July 2014
- Published by Elsevier in Molecular Therapy
- Vol. 22 (7) , 1310-1319
Colocalized Delivery of Rapamycin and Paclitaxel to Tumors Enhances Synergistic Targeting of the PI3K/Akt/mTOR Pathway
- 1 July 2014
- Published by Elsevier in Molecular Therapy
- Vol. 22 (7) , 1310-1319
Open AccessColocalized Delivery of Rapamycin and Paclitaxel to Tumors Enhances Synergistic Targeting of the PI3K/Akt/mTOR Pathway
- 1 April 2014
- Published by Elsevier in Cancer Letters
- Vol. 345 (1) , 48-55
Serum biomarkers for personalization of nanotherapeutics-based therapy in different tumor and organ microenvironments
- 1 April 2014
- Published by Elsevier in Cancer Letters
- Vol. 345 (1) , 48-55
Serum biomarkers for personalization of nanotherapeutics-based therapy in different tumor and organ microenvironments
- 24 March 2014
- Published by Taylor & Francis in Journal of Microencapsulation
- Vol. 31 (5) , 501-507
Evaluation of anticancer activity of celastrol liposomes in prostate cancer cells
Context: Celastrol, a natural compound derived from the herb Tripterygium wilfordii, is known to have anticancer activity, but is not soluble in water. Objective: Formation of celastrol liposomes, to avoid the use of toxic solubilising agents. Materials and methods: Two different formulations of PEGylated celastrol liposomes were fabricated. Liposomal characteristics and serum stability were determined using dynamic light scattering. Drug entrapment efficacy and drug release were measured spectrophotometrically. Cellular internalisation and anticancer activity was measured in prostate cancer cells. Results: Liposomal celastrol displayed efficient serum stability, cellular internalisation and anticancer activity, comparable to that of the free drug reconstituted in dimethyl sulfoxide. Discussion and conclusion: Liposomal celastrol can decrease the viability of prostate cancer cells, while eliminating the need for toxic solubilising agents.
- 24 March 2014
- Published by Taylor & Francis in Journal of Microencapsulation
- Vol. 31 (5) , 501-507
Evaluation of anticancer activity of celastrol liposomes in prostate cancer cells
Context: Celastrol, a natural compound derived from the herb Tripterygium wilfordii, is known to have anticancer activity, but is not soluble in water. Objective: Formation of celastrol liposomes, to avoid the use of toxic solubilising agents. Materials and methods: Two different formulations of PEGylated celastrol liposomes were fabricated. Liposomal characteristics and serum stability were determined using dynamic light scattering. Drug entrapment efficacy and drug release were measured spectrophotometrically. Cellular internalisation and anticancer activity was measured in prostate cancer cells. Results: Liposomal celastrol displayed efficient serum stability, cellular internalisation and anticancer activity, comparable to that of the free drug reconstituted in dimethyl sulfoxide. Discussion and conclusion: Liposomal celastrol can decrease the viability of prostate cancer cells, while eliminating the need for toxic solubilising agents.
- 1 February 2014
- Published by Elsevier in Colloids and Surfaces B: Biointerfaces
- Vol. 114, 294-300
Shrinkage of pegylated and non-pegylated liposomes in serum
- 1 February 2014
- Published by Elsevier in Colloids and Surfaces B: Biointerfaces
- Vol. 114, 294-300
Shrinkage of pegylated and non-pegylated liposomes in serum
- 1 February 2014
- Published by Elsevier in The Breast
- Vol. 23 (1) , 10-18
Emerging nanotherapeutic strategies in breast cancer
- 1 February 2014
- Published by Elsevier in The Breast
- Vol. 23 (1) , 10-18
Emerging nanotherapeutic strategies in breast cancer
Polyarginine Induces an Antitumor Immune Response through Binding to Toll‐Like Receptor 4
A novel function of polyarginine as an activator of the immune system is reported. Single‐molecule fluorescence imaging and single‐molecule force measurements demonstrate that polyarginine binds specifically to the toll‐like receptor 4 (TLR4), inducing receptor dimerization and activation. Moreover, polyarginine induced immune activation inhibits tumor growth. These results suggest the potential use of polyarginine for cancer immunotherapy.
Polyarginine Induces an Antitumor Immune Response through Binding to Toll‐Like Receptor 4
A novel function of polyarginine as an activator of the immune system is reported. Single‐molecule fluorescence imaging and single‐molecule force measurements demonstrate that polyarginine binds specifically to the toll‐like receptor 4 (TLR4), inducing receptor dimerization and activation. Moreover, polyarginine induced immune activation inhibits tumor growth. These results suggest the potential use of polyarginine for cancer immunotherapy.
- 6 November 2013
- Published by Wiley in FEBS Letters
- Vol. 587 (24) , 3912-3920
Expression of Concern: Live‐cell single‐molecule imaging reveals clathrin and caveolin‐1 dependent docking of SMAD4 at the cell membrane
Transforming growth factor β (TGF‐β) signaling is important for many biological processes. Although the sequential events of this cascade are known, the dynamics remain speculative. Here, live‐cell single‐molecule total internal reflection fluorescence microscopy was used to monitor the dynamics of SMAD4, a TGF‐β downstream effector, in MDA‐MB‐231 breast cancer cells. Contrary to previous belief, SMAD4 was detectable at the cytoplasmic membrane, displaying two subpopulations with different membrane docking behaviors. These subpopulations were regulated by clathrin and caveolin‐1, and had opposing roles in the nuclear shuttling of SMAD4 and the subsequent transcriptional regulation of genes associated with cell migration. The notion that membrane‐docking behaviors of downstream molecules could predict the cellular response to growth factors may revolutionize the way we view cell signaling.
- 6 November 2013
- Published by Wiley in FEBS Letters
- Vol. 587 (24) , 3912-3920
Expression of Concern: Live‐cell single‐molecule imaging reveals clathrin and caveolin‐1 dependent docking of SMAD4 at the cell membrane
Transforming growth factor β (TGF‐β) signaling is important for many biological processes. Although the sequential events of this cascade are known, the dynamics remain speculative. Here, live‐cell single‐molecule total internal reflection fluorescence microscopy was used to monitor the dynamics of SMAD4, a TGF‐β downstream effector, in MDA‐MB‐231 breast cancer cells. Contrary to previous belief, SMAD4 was detectable at the cytoplasmic membrane, displaying two subpopulations with different membrane docking behaviors. These subpopulations were regulated by clathrin and caveolin‐1, and had opposing roles in the nuclear shuttling of SMAD4 and the subsequent transcriptional regulation of genes associated with cell migration. The notion that membrane‐docking behaviors of downstream molecules could predict the cellular response to growth factors may revolutionize the way we view cell signaling.
- 1 July 2013
- Published by Elsevier in Cancer Letters
- Vol. 334 (2) , 202-210
Serum peptidomic biomarkers for pulmonary metastatic melanoma identified by means of a nanopore-based assay
- 1 July 2013
- Published by Elsevier in Cancer Letters
- Vol. 334 (2) , 202-210
Serum peptidomic biomarkers for pulmonary metastatic melanoma identified by means of a nanopore-based assay
- Open Access
- 8 May 2013
- Published by Springer Nature in Breast Cancer Research
- Vol. 15 (3) , 205
Delivery of gene silencing agents for breast cancer therapy
The discovery of RNA interference has opened the door for the development of a newclass of cancer therapeutics. Small inhibitory RNA oligos are being designed tospecifically suppress expression of proteins that are traditionally considerednondruggable, and microRNAs are being evaluated to exert broad control of geneexpression for inhibition of tumor growth. Since most naked molecules are notoptimized for in vivo applications, the gene silencing agents need to bepackaged into delivery vehicles in order to reach the target tissues as theirdestinations. Thus, the selection of the right delivery vehicles serves as a crucialstep in the development of cancer therapeutics. The current review summarizes thestatus of gene silencing agents in breast cancer and recent development of candidatecancer drugs in clinical trials. Nanotechnology-based delivery vectors for theformulation and packaging of gene silencing agents are also described.
- 8 May 2013
- Published by Springer Nature in Breast Cancer Research
- Vol. 15 (3) , 205
Open AccessDelivery of gene silencing agents for breast cancer therapy
The discovery of RNA interference has opened the door for the development of a newclass of cancer therapeutics. Small inhibitory RNA oligos are being designed tospecifically suppress expression of proteins that are traditionally considerednondruggable, and microRNAs are being evaluated to exert broad control of geneexpression for inhibition of tumor growth. Since most naked molecules are notoptimized for in vivo applications, the gene silencing agents need to bepackaged into delivery vehicles in order to reach the target tissues as theirdestinations. Thus, the selection of the right delivery vehicles serves as a crucialstep in the development of cancer therapeutics. The current review summarizes thestatus of gene silencing agents in breast cancer and recent development of candidatecancer drugs in clinical trials. Nanotechnology-based delivery vectors for theformulation and packaging of gene silencing agents are also described.